Cargando…

Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens

AIM: There is a critical need for effective therapies that are immediately available to control the spread of COVID-19 disease. MATERIAL & METHODS: Gamunex(®)-C and Flebogamma(®) DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested using ELISA techniques for antibodies against se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Díez, José-María, Romero, Carolina, Gajardo, Rodrigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222542/ https://www.ncbi.nlm.nih.gov/pubmed/32397847 http://dx.doi.org/10.2217/imt-2020-0095

Ejemplares similares

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
por: Díez, José María, et al.
Publicado: (2020)

Effective presence of antibodies against common human coronaviruses in immunoglobulin medicinal products
por: Díez, José María, et al.
Publicado: (2022)

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
por: Díez, José María, et al.
Publicado: (2021)

Surveillance of anti-SARS-CoV-2 antibodies in plasma pools and in immunoglobulin medicinal products manufactured since 2020 has shown high neutralizing activity against SARS-CoV-2 and current variants
por: Romero, Carolina, et al.
Publicado: (2023)

Anti-Arbovirus Antibodies Cross-React With Severe Acute Respiratory Syndrome Coronavirus 2
por: Hunsawong, Taweewun, et al.
Publicado: (2022)

Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019
por: Sakoulas, George, et al.
Publicado: (2020)

Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)
por: Díez, José María, et al.
Publicado: (2022)

Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products
por: Romero, Carolina, et al.
Publicado: (2021)

Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update
por: Romero, Carolina, et al.
Publicado: (2022)

Generation and Characterization of Anti-CD34 Monoclonal Antibodies that React with Hematopoietic Stem Cells
por: Aghebati Maleki, Leili, et al.
Publicado: (2014)

Induction of Cross-Reacting Antibodies Against the COVID-19 by BCG Vaccination in the Mouse Model
por: Rahali, Nadia, et al.
Publicado: (2022)

Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice
por: Hohenadl, Christine, et al.
Publicado: (2014)

Invertebrate recognition protein cross-reacts with an immunoglobulin idiotype
Publicado: (1984)

Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
por: Upasani, Vinit, et al.
Publicado: (2023)

Tumour-associated antigens reacting with cytotoxic antibodies in serum of hepatoma-bearing rats.
por: Lando, P., et al.
Publicado: (1981)

Monoclonal antibody to intermediate filament antigen cross-reacts with higher plant cells
Publicado: (1985)

Hemophore-like proteins produced by periodontopathogens are recognized by the host immune system and react differentially with IgG antibodies
por: Śmiga, Michał, et al.
Publicado: (2023)

Detection of Antibodies Against Human Leukocyte Antigen Class II in the Sera of Patients Receiving Intravenous Immunoglobulin
por: Takamatsu, Hiroyuki, et al.
Publicado: (2021)

Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
por: Galeotti, Caroline, et al.
Publicado: (2020)

Affinity-Purified Respiratory Syncytial Virus Antibodies from Intravenous Immunoglobulin Exert Potent Antibody-Dependent Cellular Cytotoxicity
por: Gupta, Nimesh, et al.
Publicado: (2013)

Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin
por: Suzuki, Yasuhito, et al.
Publicado: (2020)

THE EFFECT OF CROSS-REACTING ANTIGENS ON THE TOLERANT STATE
por: Cinader, B., et al.
Publicado: (1967)

OX130 Monoclonal Antibody Recognizes Human SIRPβ1 but Cross-Reacts on SIRPα from One Allele
por: Hatherley, Deborah, et al.
Publicado: (2016)

Intravenous immunoglobulin (IVIg) provides protection against endothelial cell dysfunction and death in ischemic stroke
por: Widiapradja, Alexander, et al.
Publicado: (2014)

Intravenous human immunoglobulin utilization patterns and cost analysis in a Malaysian tertiary referral hospital
por: Choo, Shea Jiun, et al.
Publicado: (2022)

React and React Native
por: Boduch, Adam
Publicado: (2017)

React and React Native
por: Boduch, Adam
Publicado: (2020)

Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease
por: Danieli, Maria Giovanna, et al.
Publicado: (2021)

Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.
por: Boxer, G. M., et al.
Publicado: (1994)

Specific Antibodies Reacting with SV40 Large T Antigen Mimotopes in Serum Samples of Healthy Subjects
por: Tognon, Mauro, et al.
Publicado: (2016)

Detection of Bone‐type Alkaline Phosphatase by Monoclonal Antibodies Reacting with Human Osteosarcoma‐associated Antigen
por: Nagoya, Satoshi, et al.
Publicado: (1991)

Antifungal antibodies present in intravenous immunoglobulin derived from China
por: Wang, Yanfang, et al.
Publicado: (2023)

Phosphorus Allocation to Leaves of Beech Saplings Reacts to Soil Phosphorus Availability
por: Meller, Sonia, et al.
Publicado: (2019)

Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin
por: Abghari, Pamella F., et al.
Publicado: (2017)

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens
por: Chouksey, Akhilesh, et al.
Publicado: (2005)

Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
por: Klingler, Jéromine, et al.
Publicado: (2020)

Rapid screening for severe acute respiratory syndrome coronavirus 2 infection with a combined point-of-care antigen test and an immunoglobulin G antibody test
por: Mori, Kosuke, et al.
Publicado: (2022)

Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses
por: Orange, Jordan S., et al.
Publicado: (2015)

The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin
por: Miller, Aaron L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m0045vdbnm9rms5jkbuocsoo3p